IN2015DN00845A - - Google Patents

Download PDF

Info

Publication number
IN2015DN00845A
IN2015DN00845A IN845DEN2015A IN2015DN00845A IN 2015DN00845 A IN2015DN00845 A IN 2015DN00845A IN 845DEN2015 A IN845DEN2015 A IN 845DEN2015A IN 2015DN00845 A IN2015DN00845 A IN 2015DN00845A
Authority
IN
India
Prior art keywords
oxoisoindolin
morpholinomethyl
dione
piperidine
oxy
Prior art date
Application number
Inventor
John F Traverse
Chengmin Zhang
Gregg B Feigelson
Benjamin M Cohen
William W Leong
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of IN2015DN00845A publication Critical patent/IN2015DN00845A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided are processes for the preparation of enantiomerically enriched or enantiomerically pure 3-(4-((4-(morpholinomethyl) benzyl)oxy)- 1 -oxoisoindolin-2-yl)piperidine- 2,6-dione, or a pharmaceutically acceptable form thereof.
IN845DEN2015 2012-08-09 2013-08-08 IN2015DN00845A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261681477P 2012-08-09 2012-08-09
PCT/US2013/054099 WO2014025978A1 (en) 2012-08-09 2013-08-08 Processes for the preparation of (s)-3-4-((4-(morpholinomethyl) benzyl)oxy)-1-oxoisoindolin-2-yl) piperidine-2,6-dione and pharmaceutically acceptable forms thereof

Publications (1)

Publication Number Publication Date
IN2015DN00845A true IN2015DN00845A (en) 2015-06-12

Family

ID=49035933

Family Applications (1)

Application Number Title Priority Date Filing Date
IN845DEN2015 IN2015DN00845A (en) 2012-08-09 2013-08-08

Country Status (19)

Country Link
US (2) US9309220B2 (en)
EP (2) EP3466942B1 (en)
JP (1) JP6444866B2 (en)
KR (1) KR20150041650A (en)
CN (1) CN104718202B (en)
AU (1) AU2013299559B2 (en)
BR (1) BR112015002183A2 (en)
CA (2) CA2879151C (en)
CR (1) CR20150051A (en)
EC (1) ECSP15004585A (en)
ES (2) ES2712652T3 (en)
HK (1) HK1211577A1 (en)
IL (1) IL236925A0 (en)
IN (1) IN2015DN00845A (en)
MX (2) MX2015001633A (en)
PH (1) PH12015500214A1 (en)
RU (1) RU2015108057A (en)
SG (1) SG11201500984QA (en)
WO (1) WO2014025978A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114856C2 (en) 2010-02-11 2017-08-10 Селджин Корпорейшн METHODS OF TREATMENT WITH THE APPLICATION OF ARYLMETOXISOINDOLINE DERIVATIVES
AU2012236655B2 (en) 2011-03-28 2016-09-22 Deuterx, Llc, 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
EP2943201B2 (en) 2013-01-14 2020-07-29 Deuterx, LLC 3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
WO2014116573A1 (en) 2013-01-22 2014-07-31 Celgene Corporation Processes for the preparation of isotopologues of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and pharmaceutically acceptable salts thereof
US9290475B2 (en) 2013-03-14 2016-03-22 Deuterx, Llc 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
US10717703B2 (en) 2017-08-21 2020-07-21 Celgene Corporation Processes for the preparation of (S)-tert-butyl 4,5-diamino-5-oxopentanoate
AU2019351811B2 (en) 2018-10-01 2025-01-02 Celgene Corporation Combination therapy for the treatment of cancer
CN110194760B (en) * 2019-05-27 2021-08-17 浙江农林大学暨阳学院 Method for preparing 3-benzylidene-2-(7'-quinoline)-2,3-dihydro-isoindol-1-one compounds
MX2022006626A (en) * 2019-12-02 2022-06-27 Celgene Corp Therapy for the treatment of cancer.
CN113896711A (en) 2020-07-06 2022-01-07 北京诺诚健华医药科技有限公司 Heterocyclic immunomodulators
WO2024064646A1 (en) 2022-09-20 2024-03-28 Celgene Corporation Salts and solid forms of (s)- or racemic 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and methods of using the same
WO2024212883A1 (en) * 2023-04-11 2024-10-17 上海科胜药物研发有限公司 Preparation method for aryl methoxy isoindoline derivative

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629360B2 (en) * 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
EP1797068B1 (en) * 2004-09-03 2013-10-09 Celgene Corporation Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines
RS52704B (en) * 2005-06-30 2013-08-30 Celgene Corporation Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl) isoindoline-1,3-dione compounds
EP3101017B1 (en) 2007-03-20 2019-06-12 Celgene Corporation 4'-o-substituted isoindoline derivatives and compositions comprising and methods of using the same
UA114856C2 (en) * 2010-02-11 2017-08-10 Селджин Корпорейшн METHODS OF TREATMENT WITH THE APPLICATION OF ARYLMETOXISOINDOLINE DERIVATIVES
CA2793312C (en) 2010-03-08 2016-06-14 Natco Pharma Limited Anhydrous lenalidomide form-i
WO2013126394A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione

Also Published As

Publication number Publication date
ES2712652T3 (en) 2019-05-14
US9975872B2 (en) 2018-05-22
MX385058B (en) 2025-03-14
EP3466942B1 (en) 2022-04-20
CN104718202A (en) 2015-06-17
EP2882736B1 (en) 2019-01-09
CA2879151C (en) 2021-03-30
CA3108974A1 (en) 2014-02-13
KR20150041650A (en) 2015-04-16
US20160251333A1 (en) 2016-09-01
EP2882736A1 (en) 2015-06-17
PH12015500214A1 (en) 2015-04-27
BR112015002183A2 (en) 2017-07-04
AU2013299559B2 (en) 2017-08-17
HK1211577A1 (en) 2016-05-27
ECSP15004585A (en) 2015-12-31
CA2879151A1 (en) 2014-02-13
US9309220B2 (en) 2016-04-12
MX2015001633A (en) 2015-04-08
WO2014025978A1 (en) 2014-02-13
IL236925A0 (en) 2015-03-31
JP2015524481A (en) 2015-08-24
CA3108974C (en) 2023-04-04
AU2013299559A1 (en) 2015-02-05
CR20150051A (en) 2015-05-11
RU2015108057A (en) 2016-09-27
US20140046058A1 (en) 2014-02-13
ES2914876T3 (en) 2022-06-17
CN104718202B (en) 2018-11-20
JP6444866B2 (en) 2018-12-26
EP3466942A1 (en) 2019-04-10
SG11201500984QA (en) 2015-04-29

Similar Documents

Publication Publication Date Title
IN2015DN00845A (en)
IL288506A (en) Methods of treating cancer using 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
PH12015500275A1 (en) Salts and solid forms of (s)-3-(4-((4-morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione and compositions comprising and methods of using the same
IL244494A0 (en) Formulations of 3-(4-((4-(morpholinomethyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione
TW201144301A (en) Processes for preparing linezolid
PH12015502477A1 (en) Synthesis of 3-(5-amino-2-methyl-4-oxoquinazolin-3(4h)-yl) piperidine-2,6-dione